GlassScriptPhysician profile
Megan E S Frank
NPI 1821290313
$5,610.34
in general payments reported to CMS, 2019-2025
57 companies · $99.33 in 2025
The $99.33 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,970 · 2020: $1,178 · 2021: $1,361 · 2022: $315 · 2023: $626 · 2024: $60.28 · 2025: $99.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $776 · Education: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $776.01 |
| Education | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $711.81 | 2019-2022 | |
| Abbvie INC. | $363.39 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $346.39 | 2019-2021 | |
| Exact Sciences Corporation | $282.04 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $279.50 | 2019-2023 | |
| Amarin Pharma, INC. | $256.14 | 2019-2021 | |
| Lilly USA, LLC | $248.72 | 2019-2022 | |
| Amgen INC. | $245.60 | 2019-2023 | Prolia, Evenity |
| Mannkind Corporation | $218.89 | 2023 | Afrezza |
| Glaxosmithkline, LLC. | $192.57 | 2019-2023 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $183.62 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $168.62 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $150.58 | 2019-2021 | |
| Allergan, INC. | $143.77 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.83 | 2019-2021 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Frank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.